Heart / Stroke-RelatedCoronary-Artery Disease Heart / Stroke-RelatedCardiologyFamily PracticeHematology & OncologyInternal MedicinePathologyPharmacyCardiovascular DiseasesCoronary-Artery DiseaseConditionsGenetic Disorders
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, March 29 (HealthDay News) -- For patients who undergo percutaneous coronary intervention (PCI), point-of-care genetic testing is feasible and identifies carriers of a CYP2C19*2 allele with high sensitivity and specificity, according to a proof-of-concept study published online March 29 in The Lancet.
Jason D. Roberts, M.D., from the University of Ottawa Heart Institute in Canada, and colleagues enrolled 200 patients undergoing PCI for acute coronary syndrome or stable angina to rapid point-of-care genotyping or standard treatment. Those in the rapid genotyping group were screened for the CYP2C19*2 allele and were given 10 mg prasugrel daily (carriers) or 75 mg clopidogrel daily (noncarriers). Those in the standard treatment group received 75 mg clopidogrel daily.
After randomization, the researchers found that 187 patients completed follow-up. In each group, 23 individuals carried at least one CYP2C19*2 allele. In the rapid genotyping group, none of the carriers had high on-treatment platelet reactivity after one week of dual antiplatelet treatment, whereas seven of the carriers in the standard treatment group did (P = 0.0092). The sensitivity and specificity of the point-of-care genetic test were 100 and 99.3 percent, respectively.
"Point-of-care genetic testing after PCI can be done effectively at the bedside and treatment of identified CYP2C19*2 carriers with prasugrel can reduce high on-treatment platelet reactivity," the authors write.
One of the authors disclosed financial ties to the pharmaceutical industry and Spartan Biosciences, which funded the RAPID GENE study and developed the point-of-care genetic test used in the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on March 29, 2012
Read this Next
Related Articles from Hematology & Oncology